CR10764A - Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato - Google Patents

Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato

Info

Publication number
CR10764A
CR10764A CR10764A CR10764A CR10764A CR 10764 A CR10764 A CR 10764A CR 10764 A CR10764 A CR 10764A CR 10764 A CR10764 A CR 10764A CR 10764 A CR10764 A CR 10764A
Authority
CR
Costa Rica
Prior art keywords
crystal
chlorophenyl
novedoso
hydroxyethyl carbamate
carbamate
Prior art date
Application number
CR10764A
Other languages
English (en)
Inventor
Peterson Matthew
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR10764A publication Critical patent/CR10764A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

La presente invencion se relaciona con un cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato, composiciones farmaceuticas que comprenden este cristal y metodos para elaborar y utilizar este cristal.
CR10764A 2006-10-06 2009-05-05 Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato CR10764A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82839206P 2006-10-06 2006-10-06

Publications (1)

Publication Number Publication Date
CR10764A true CR10764A (es) 2009-09-14

Family

ID=39283405

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10764A CR10764A (es) 2006-10-06 2009-05-05 Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato

Country Status (19)

Country Link
US (1) US7632963B2 (es)
EP (1) EP2076258A4 (es)
JP (1) JP2010505856A (es)
KR (1) KR20090076958A (es)
CN (1) CN101657195A (es)
AU (1) AU2007307029A1 (es)
BR (1) BRPI0718131A2 (es)
CA (1) CA2665573A1 (es)
CO (1) CO6180504A2 (es)
CR (1) CR10764A (es)
EA (1) EA200970355A1 (es)
GT (1) GT200900076A (es)
IL (1) IL198016A0 (es)
MX (1) MX2009003755A (es)
NI (1) NI200900050A (es)
NO (1) NO20091771L (es)
SV (1) SV2009003211A (es)
WO (1) WO2008045391A2 (es)
ZA (1) ZA200903095B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
CN104870421A (zh) * 2011-12-27 2015-08-26 比皮艾思药物研发有限公司 用于预防或治疗als的苯基氨基甲酸酯化合物
EP4382509A1 (en) * 2021-08-05 2024-06-12 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate crystalline form and method for preparing same
KR102399807B1 (ko) * 2021-08-05 2022-05-20 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
WO2001019368A1 (en) * 1999-09-10 2001-03-22 Dainippon Ink And Chemicals, Inc. Quinolinone derivative preparations and process for producing the same
NZ527990A (en) * 2001-02-27 2006-01-27 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating neurodegenerative disorders
AU2002358806B2 (en) * 2001-12-21 2009-09-10 Sk Biopharmaceuticals Co., Ltd. Process for preparing 2-(substituted phenyl)-2-hydroxy-ethyl carbamates
US7772240B2 (en) 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
RS51269B (sr) * 2004-09-16 2010-12-31 Janssen Pharmaceutica N.V. Upotreba 2-fenil-1,2-etandiol-(di)karbamata za tretiranje epileptogeneze
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Also Published As

Publication number Publication date
NO20091771L (no) 2009-05-05
CN101657195A (zh) 2010-02-24
KR20090076958A (ko) 2009-07-13
ZA200903095B (en) 2010-07-28
WO2008045391A3 (en) 2008-06-12
US20080085930A1 (en) 2008-04-10
CA2665573A1 (en) 2008-04-17
BRPI0718131A2 (pt) 2013-11-05
WO2008045391A2 (en) 2008-04-17
MX2009003755A (es) 2009-07-10
EA200970355A1 (ru) 2009-12-30
AU2007307029A1 (en) 2008-04-17
EP2076258A4 (en) 2011-09-28
SV2009003211A (es) 2009-11-24
IL198016A0 (en) 2009-12-24
JP2010505856A (ja) 2010-02-25
EP2076258A2 (en) 2009-07-08
CO6180504A2 (es) 2010-07-19
US7632963B2 (en) 2009-12-15
GT200900076A (es) 2010-05-18
NI200900050A (es) 2010-02-01

Similar Documents

Publication Publication Date Title
CR10479A (es) Modulares bencimidazolicos de vr1
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
HN2007000407A (es) Compuesto de biaril eter urea
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
BRPI0509184A (pt) composições farmacêuticas
CR9569A (es) Modificaciones cristalinas de la piraclostrobina
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
CR11548A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
UY33735A (es) Compuestos antivirales
CR11106A (es) Inhibidores de cinasa p710 s6
TW200621313A (en) Pharmaceutical compositions
HN2006037713A (es) Compuestos utiles en terapia
GT200500130A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
CR10766A (es) Inhibidores de metaloproteasa derivados de heterociclicos
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
HN2006029142A (es) Proceso
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
GT200500358A (es) Compuestos organicos
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
CR10764A (es) Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato
UY29817A1 (es) Nuevos compuestos de azetidina, composiciones farmacéuticas que los contienen, procesos de preparación y uso terapéutico de los mismos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)